DOPTELET (avatrombopag) Now Available at Biologics by McKesson

March 19, 2020

Biologics selected for distribution network based on its expertise in high-touch support for oncology and complex disease patients

CARY, N.C., March 19, 2020Biologics by McKesson, an independent specialty pharmacy for oncology and complex care, was selected by AkaRx, Inc., a subsidiary of Dova Pharmaceuticals, Inc., as a specialty pharmacy provider in a limited distribution network for DOPTELET® (avatrombopag). Dova, which recently received approval from the U.S. Food & Drug Administration (FDA) for a new treatment indication for DOPTELET, selected Biologics to help provide high-touch clinical support to patients.

DOPTELET is a thrombopoietin (TPO) receptor agonist which the FDA originally approved for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. A supplemental New Drug Application (sNDA) was approved in June 2019 that expanded the use of DOPTELET to include the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Chronic ITP is a rare autoimmune bleeding disorder characterized by a low number of platelets, affecting approximately 60,000 adults in the United States.

“We are excited to work with Dova to help make this therapy available to new patients through our comprehensive access services and best-in-class clinical care management designed to both educate providers and help keep patients on therapy,” said Brandon Tom, vice president of Commercial Services with Biologics.

Biologics is committed to and recognized for its high level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes a pharmacist with in-depth knowledge of therapies, an experienced nurse and a financial counselor who is familiar with various financial assistance programs and organizations that help patients. This highly-skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As part of McKesson Life Sciences, a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.

About Dova Pharmaceuticals, Inc.

Dova, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia.

Public Relations Contact